Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Faculty disclosure
- Chronic obstructive pulmonary disease (COPD)
- Learning objectives: Clinical characteristics
- COPD: key points
- Asthma vs. COPD: clinical characteristics
- Asthma vs. COPD: clinical differences
- COPD is NOT Asthma!
- Asthma vs. COPD: site & cells of inflammation
- Airway obstruction in asthma & COPD
- Learning objectives: Pathophysiology
- COPD is a small airways disease
- Small vs. large airways
- Inflammatory disorder involving small airways
- Airflow limitation in the small airways
- COPD physiology : small airways disease
- Learning objectives: Assessing the lungs
- Assessing the lungs
- Clinical imaging
- Physiology – spirometry
- FEV1 is a strong predictor of mortality in COPD
- Small airway disease: characteristics
- Assessment of small airway dysfunction
- Lung volumes
- Spirometry
- Flow-volume loops
- Novel spirometric measure
- Forced oscillation technique
- Low frequencies detect small airways
- Small-airway dysfunction among COPD patients
- Small airways & health status CAT score
- Learning objectives: Disease classification
- COPD classification
- GOLD 2014: management of COPD
- GOLD 2017: refined ABCD assessment tool
- Learning objectives: Therapeutic management
- GOLD 2017: recommendations for COPD
- Pneumonia and ICS in COPD
- Biomarker of stratifying ICS-sensitive COPD?
- Eosinophil in COPD: just another biomarker?
- Uncertainties in blood eosinophils
- Triple therapy in COPD
- When to use ICS in COPD management
- Thanks
Topics Covered
- Clinical characteristics and pathophysiology of COPD
- Pathophysiology of COPD
- Assessing the lungs in COPD
- COPD disease classification
- Therapeutic management of COPD
Links
Series:
- Advances in Chronic Obstructive Pulmonary Disease (COPD)
- Periodic Reports: Advances in Clinical Interventions and Research Platforms
Categories:
Therapeutic Areas:
Talk Citation
Usmani, O.S. (2017, December 31). Updates in chronic obstructive pulmonary disease (COPD) [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 20, 2024, from https://doi.org/10.69645/FDFR6952.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Omar S. Usmani, Speaker’s bureau: Takeda, Chiesi ; Grant/Research Support (Principal Investigator): Chiesi, GSK, Astra Zeneca, Takeda.
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
Hello. I'm Omar Usmani.
I'm a Reader in Respiratory Medicine at
Imperial College London and a Consultant Physician at the Royal Brompton Hospital.
I'm going to be talking about updates in Chronic Obstructive Pulmonary Disease, COPD,
particularly those in the last two years that have had an influence on
our clinical practice and may also help us guide research in the future years.
0:23
And this is my faculty disclosure and I wanted to emphasize that I have
no shares in any of the company and I have
no relationship of any kind with the tobacco industry.
0:34
So, I will review the anatomy and the pathology,
and how that relates to the physiology and importantly,
how that determines our management and treatment and
pharmacological approach of patients with COPD in the clinic.
0:49
So, I will review five key areas: clinical characteristics,
the Pathophysiology of patients with COPD,
how we're assessing the lungs and novel methods of assessing
the lungs that have appeared over the last few years,
the new disease classifications we have seen particularly this year, and also,
how that reflects on our new approach to
the therapeutic management of patients with COPD.
1:14
So, this year, we have seen the Global Initiative of
Obstructive Lung Disease or GOLD update their document.
And there are five key points related to COPD.
The first that we are aware of is that COPD is
a preventable and treatable disease that is
characterized by persistent respiratory symptoms.
Importantly, is point two,
and that the symptoms of dyspnea, cough,
and sputum production may actually be under-reported,
and a key point for us to reflect on this is our ability
to assess patients with COPD and find these patients,
not just in secondary care, but also primary care and using
Spirometry in an effective manner to find these patients.
The third point we see is that certainly
tobacco smoking is an important risk factor for COPD,
but a lot of research over the last few years has shown that biomass fuel exposure
and air pollution certainly may contribute to the manifestation of patients with COPD.
We also need to realize that COPD can be punctuated by periods of
acute worsening of respiratory symptoms called
exacerbations and we will pick up on this a little bit later.